197 related articles for article (PubMed ID: 22323422)
1. Successful rechallenge after ixabepilone-induced radiation recall dermatitis using an alternative dosing strategy.
Ford JN; Newton M; Jordan C; Abraham J
J Oncol Pharm Pract; 2013 Mar; 19(1):89-92. PubMed ID: 22323422
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone (Ixempra) for breast cancer.
Med Lett Drugs Ther; 2008 Jan; 50(1278):7-8. PubMed ID: 18219261
[No Abstract] [Full Text] [Related]
3. Ixabepilone: new drug. Similar to taxanes, but no better.
Prescrire Int; 2009 Aug; 18(102):160. PubMed ID: 19743574
[No Abstract] [Full Text] [Related]
4. Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
Egerton N
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1005-12. PubMed ID: 20886213
[TBL] [Abstract][Full Text] [Related]
5. Epothilones: clinical update and future directions.
Donovan D; Vahdat LT
Oncology (Williston Park); 2008 Apr; 22(4):408-16; discussion 416, 421, 424 passim. PubMed ID: 18472615
[TBL] [Abstract][Full Text] [Related]
6. An illustrated case of doxorubicin-induced radiation recall dermatitis and a review of the literature.
Haas RL; de Klerk G
Neth J Med; 2011 Feb; 69(2):72-5. PubMed ID: 21411843
[TBL] [Abstract][Full Text] [Related]
7. Alternative dosing schedules and administration updates for ixabepilone.
Kossoff E
J Oncol Pharm Pract; 2011 Sep; 17(3):203-8. PubMed ID: 20215481
[TBL] [Abstract][Full Text] [Related]
8. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
9. Approved agents for metastatic breast cancer.
Fornier MN
Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
[TBL] [Abstract][Full Text] [Related]
10. Carcinoma erysipeloides: an unusual presentation mimicking radiation dermatitis.
Gugle A; Malpathak V; Zawar V; Deshmukh M; Kote R
Dermatol Online J; 2008 Feb; 14(2):26. PubMed ID: 18700129
[No Abstract] [Full Text] [Related]
11. Epothilones in the treatment of cancer.
Larkin JM; Kaye SB
Expert Opin Investig Drugs; 2006 Jun; 15(6):691-702. PubMed ID: 16732719
[TBL] [Abstract][Full Text] [Related]
12. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.
Villanueva C; Vuillemin AT; Demarchi M; Bazan F; Chaigneau L; Pivot X
Womens Health (Lond); 2009 Mar; 5(2):115-21. PubMed ID: 19245349
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
Vahdat L
Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
[TBL] [Abstract][Full Text] [Related]
15. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Boehnke Michaud L
J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
[TBL] [Abstract][Full Text] [Related]
16. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
17. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Yardley DA
Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
19. Ixabepilone in metastatic breast cancer: complement or alternative to taxanes?
Tan AR; Toppmeyer DL
Clin Cancer Res; 2008 Nov; 14(21):6725-9. PubMed ID: 18980963
[No Abstract] [Full Text] [Related]
20. Radiation recall dermatitis after pre-sensitization with pegylated liposomal doxorubicin.
Gzell CE; Carroll SL; Suchowerska N; Beith J; Tan K; Scolyer RA
Cancer Invest; 2009 May; 27(4):397-401. PubMed ID: 19219651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
